Cited by 129Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study

Open access
Jack, Clifford R, Therneau, Terry M, Wiste, Heather J, Weigand, Stephen D, Knopman, David S, Lowe, Val J, Mielke, Michelle M, Vemuri, Prashanthi +6 more·2016·The Lancet Neurology

Abstract

Background In a 2014 cross-sectional analysis, we showed that amyloid and neurodegeneration biomarker states in participants with no clinical impairment varied greatly with age, suggesting dynamic within-person processes. In this longitudinal study, we aimed to estimate rates of transition from a less to a more abnormal biomarker state by age in individuals without dementia, as well as to assess rates of transition to dementia from an abnormal state.Methods Participants from the Mayo Clinic Study of Aging (Olmsted County, MN, USA) without dementia at baseline were included in this study, a subset of whom agreed to multimodality imaging. Amyloid PET (with (11)C-Pittsburgh compound B) was used to classify individuals as amyloid positive (A(+)) or negative (A(-)). (18)F-fluorodeoxyglucose ((18)F-FDG)-PET and MRI were used to classify individuals as neurodegeneration positive (N(+)) or negative (N(-)). We used all observations, including those from participants who did not have imaging results, to construct a multistate Markov model to estimate four different age-specific biomarker state transition rates: A(-)N(-) to A(+)N(-); A(-)N(-) to A(-)N(+) (suspected non-Alzheimer's pathology); A(+)N(-) to A(+)N(+); and A(-)N(+) to A(+)N(+). We also estimated two age-specific rates to dementia: A(+)N(+) to dementia and A(-)N(+) to dementia. Using these state-to-state transition rates, we estimated biomarker state frequencies by age.Findings At baseline (between Nov 29, 2004, to March 7, 2015), 4049 participants did not have dementia (3512 [87%] were clinically normal and 537 [13%] had mild cognitive impairment). 1541 individuals underwent imaging between March 28, 2006, to April 30, 2015. Transition rates were low at age 50 years and, with one exception, exponentially increased with age. At age 85 years compared with age 65 years, the rate was nearly 11-times higher (17.2 vs 1.6 per 100 person-years) for the transition from A(-)N(-) to A(-)N(+), three-times higher (20.8 vs 6.1) for A(+)N(-) to A(+)N(+), and five-times higher (13.2 vs 2.6) for A(-)N(+) to A(+)N(+). The rate of transition was also increased at age 85 years compared with age 65 years for A(+)N(+) to dementia (7.0 vs 0.8) and for A(-)N(+) to dementia (1.7 vs 0.6). The one exception to an exponential increase with age was the transition rate from A(-)N(-) to A(+)N(-), which increased from 4.0 transitions per 100 person-years at age 65 years to 6.9 transitions per 100 person-years at age 75 and then plateaued beyond that age. Estimated biomarker frequencies by age from the multistate model were similar to cross-sectional biomarker frequencies.Interpretation Our transition rates suggest that brain ageing is a nearly inevitable acceleration toward worse biomarker and clinical states. The one exception is the transition to amyloidosis without neurodegeneration, which is most dynamic from age 60 years to 70 years and then plateaus beyond that age. We found that simple transition rates can explain complex, highly interdependent biomarker state frequencies in our population.Funding National Institute on Aging, Alexander Family Professorship of Alzheimer's Disease Research, the GHR Foundation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(15)00323-3

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Jack, C. R., Therneau, T. M., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V. J., Mielke, M. M., Vemuri, P., Roberts, R. O., Machulda, M. M., Senjem, M. L., Gunter, J. L., Rocca, W. A., & Petersen, R. C.
Affiliations
Mayo Clinic (US)
Corresponding author
Jack, Clifford R
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2016-01
Volume
15
Issue
1
Pages
56-64
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2178393107
Cited by
129
References
36
Citations by year
2026: 6 · 2025: 5 · 2024: 8 · 2023: 4 · 2022: 9 · 2021: 9 · 2020: 13 · 2019: 13 · 2018: 24 · 2017: 21 · 2016: 16 · 2015: 1
FWCI
16.68
Type
journal article
Language
en
Open access
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (acceptedVersion, cc-by-nc-nd)
Funders
  • Mayo Clinic
  • National Institutes of Health (5u01ag024904-10)
  • National Institute on Aging (U01-AG-024904, R01AG034676, P50AG044170, R01AG043392, R21AG045228, U01AG006786, U01AG24904, R01AG011378, R01AG031750, R01AG037551, R01AG041851, P50AG016574)
  • National Heart, Lung, and Blood Institute (R01HL120859, U01HL096917)
  • National Cancer Institute (R01CA163803, R01CA107476, R01CA168762, P30CA015083)
  • National Institute of Nursing Research (R01NR015259)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR027065, R01AR046849)
  • National Institute of Biomedical Imaging and Bioengineering (R01EB016966)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
Keywords
amyloid PET, neurodegeneration biomarkers, dementia risk, multi-state Markov model, Alzheimer's disease, mild cognitive impairment, 11C-Pittsburgh compound B, 18F-FDG PET, brain MRI, Mayo Clinic Study of Aging, preclinical Alzheimer's disease
MeSH terms
Aged, Aged, 80 and over, Cross-Sectional Studies, Dementia, Female, Humans, Longitudinal Studies, Male, Middle Aged, Population Surveillance, Cohort Studies, Biomarkers, Disease Progression, Neurodegenerative Diseases, Plaque, Amyloid, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review